Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis) - Resistant mutants

John P. DeVincenzo, Caroline B. Hall, David W. Kimberlin, Pablo J. Sánchez, William J. Rodriguez, Barbara A. Jantausch, Lawrence Corey, Jeffrey Kahn, Janet A. Englund, JoAnn A. Suzich, Frances J. Palmer-Hill, Luis Branco, Syd Johnson, Nita K. Patel, Franco M. Piazza

Research output: Contribution to journalArticlepeer-review

56 Scopus citations


Premature infants and those with chronic lung disease or congenital heart disease are at high risk of severe respiratory syncytial virus (RSV) disease. Palivizumab (Synagis), a humanized anti-RSV monoclonal antibody, has been used extensively since 1998 to prevent severe RSV disease in high-risk infants. To monitor for possible palivizumab-resistant mutants, an immunofluorescence binding assay that predicts palivizumab neutralization of RSV was developed. RSV isolates were collected at 8 US sites from 458 infants hospitalized for RSV disease (1998-2002). Palivizumab bound to all 371 RSV isolates able to be evaluated, including 25 from active-palivizumab recipients. The palivizumab epitope appears to be highly conserved, even in infants receiving prophylaxis with palivizumab.

Original languageEnglish (US)
Pages (from-to)975-978
Number of pages4
JournalJournal of Infectious Diseases
Issue number5
StatePublished - Sep 1 2004

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases


Dive into the research topics of 'Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis) - Resistant mutants'. Together they form a unique fingerprint.

Cite this